Small molecules could be designed to modulate either total MYPT1 or LZ+ MYPT1 expression, which would both improve both the vascular response to endogenous NO and pharmacological response during the treatment of hypertension as well as a number of other diseases of the vasculature. The gene discussed is PPP1R12A; the disease is Hypertension.